Enhancement of the cellular immune response
USRE38046E1 · kind E1 · reissue
7Cited by
3References
63Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 25, 2000 |
| Grant date | Mar 25, 2003 |
| Priority date | — |
| Expiry date | Aug 25, 2020 |
Classification
- Technology area (CPC —)General
Abstract
DTH-Effector cells are printed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.